Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

INTRODUCTION. We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer. PATIENTS AND METHODS. Patients received...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Swain, Sandra M., Im, Young-Hyuck, Im, Seock-Ah, Chan, Valorie, Miles, David, Knott, Adam, Clark, Emma, Ross, Graham, Baselga, José
פורמט: Artigo
שפה:Inglês
יצא לאור: AlphaMed Press 2014
נושאים:
Breast Cancer
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077449/
https://ncbi.nlm.nih.gov/pubmed/24869931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0033
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים